SCG2 and in situ carcinoma: Secretogranin II (ScgII) showed a significant higher intensity in CIS and RRMS patients than in PrMS patients (p<0.007), whereas Protein 7B2 (P7B2) was found significantly higher only in RRMS versus PrMS patients (p = 0.05).